Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent

LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek
Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of therapies for glaucoma and other eye diseases,
today announced that the United States Patent and Trademark Office
issued a composition of matter patent for the combination of the
Company’s lead product candidate, trabodenoson, with a
prostaglandin analog for the treatment of intraocular pressure (IOP) in
patients with glaucoma. US Patent number 9,370,530 (’530 patent) further
strengthens the Company’s patent estate for trabodenoson and adds
composition of matter intellectual property protection for the
combination or kit treatment option until 2031. Trabodenoson, the
Company’s lead clinical product candidate, is a first-in-class,
selective adenosine mimetic targeting the A₁ receptor and has
been observed in Phase 2 clinical trials to reduce IOP, an important
risk factor for glaucoma. Prostaglandin analogs are currently the most
commonly used drug class for this disease.
Earlier this month, Inotek announced the initiation of their Phase 2
dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson
and latanoprost, the most commonly used prostaglandin analog
prescribed for glaucoma. Glaucoma is one of the leading causes of
blindness, and occurs when there is damage to the optic nerve, often as
a result of elevated eye pressure. While the goal of glaucoma treatment
is to preserve vision, lowering IOP has been shown to prevent
progressive vision loss. There are currently no FDC products for
glaucoma treatment that include a prostaglandin analog that are approved
in the United States, even though about half of glaucoma patients that
start treatment with a prostaglandin require a second, adjunctive
therapy to increase IOP lowering. Inotek believes an FDC of trabodenoson
with latanoprost has the potential to produce efficacy greater
than either drug alone in a convenient one-drop, once daily treatment
option for patients with glaucoma.
“The issuance of the combination patent covering the use of trabodenoson
with a prostaglandin analog is an important addition to Inotek’s
growing intellectual property portfolio. This protects use of the
combination of trabodenoson with any prostaglandin analog in a
single, convenient daily eye drop,” commented David P. Southwell,
President and Chief Executive Officer of Inotek. “We look forward to
reporting data from our recently initiated Phase 2 FDC trial of trabodenoson
and the most commonly used prostaglandin, latanoprost, in the
second half of 2017.”
The ’530 patent broadly covers the use of trabodenoson and a
prostaglandin analog as a combination, kit or method of use for reducing
IOP. Inotek’s patent estate also includes composition of matter patents
covering the trabodenoson compound through 2026 in the United
States and through 2025 abroad, the crystalline formulation of trabodenoson
used in eye drops through 2033 in the United States and patents relating
to the use of trabodenoson for reducing IOP, which expire in 2031
in the United States, and, if issued abroad, will expire in 2030.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate in
glaucoma, trabodenoson, is a first-in-class, selective adenosine
mimetic currently in Phase 3 development. Trabodenoson was
developed in Inotek’s laboratories and is designed to restore the eye’s
natural pressure control mechanism by targeting the adenosine A₁
subreceptor. Additionally, the Company is evaluating the potential for
selective adenosine mimetics to address optic neuropathies and other
degenerative retinal diseases. For more information, please visit www.inotekpharma.com.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. These forward-looking statements often
include words such as “believe,” “expect,” “anticipate,” “intend,”
“plan,” “estimate,” “seek,” “will,” “may” or similar expressions.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.